The pharmaceutical company Double Bond Pharma will present clinical Real-World Evidence data for the company’s leading candidate in neuro-oncology, SI053, at the SNO congress, the Society for Neuro-Oncology’s annual meeting in Philadelphia on November 12 to 15. This is stated in a press release. - The acceptance of our clinical dataset by SNO’s scientific program committee provides strong external recognition of SI053’s therapeutic potential, says Igor Lokot, CEO of Double Bond Pharmaceutical. The approved abstract will be published by SNO in a supplement to the peer-reviewed journal Neuro-Oncology.